Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colonoscopy | 4 | 2016 | 156 | 1.800 |
Why?
|
| Early Detection of Cancer | 4 | 2016 | 454 | 1.380 |
Why?
|
| Colorectal Neoplasms | 4 | 2016 | 561 | 1.350 |
Why?
|
| Liver Diseases | 3 | 2019 | 193 | 1.280 |
Why?
|
| Hematinics | 2 | 2017 | 52 | 1.120 |
Why?
|
| Mass Screening | 3 | 2019 | 843 | 1.000 |
Why?
|
| Hepatitis C | 3 | 2020 | 114 | 0.920 |
Why?
|
| Medical Informatics | 2 | 2013 | 71 | 0.810 |
Why?
|
| Primary Health Care | 5 | 2021 | 703 | 0.800 |
Why?
|
| Ambulatory Surgical Procedures | 3 | 2011 | 33 | 0.770 |
Why?
|
| Drug Labeling | 2 | 2017 | 32 | 0.730 |
Why?
|
| Medicare | 6 | 2017 | 319 | 0.670 |
Why?
|
| Patient Compliance | 2 | 2018 | 402 | 0.580 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 170 | 0.570 |
Why?
|
| Unnecessary Procedures | 1 | 2016 | 49 | 0.540 |
Why?
|
| Preventive Health Services | 1 | 2016 | 86 | 0.530 |
Why?
|
| United States | 13 | 2020 | 7367 | 0.530 |
Why?
|
| Breast Neoplasms | 3 | 2011 | 1536 | 0.510 |
Why?
|
| Mastectomy | 3 | 2011 | 57 | 0.470 |
Why?
|
| United States Food and Drug Administration | 3 | 2017 | 131 | 0.410 |
Why?
|
| Kidney Transplantation | 4 | 2021 | 839 | 0.410 |
Why?
|
| SEER Program | 4 | 2017 | 153 | 0.380 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 778 | 0.380 |
Why?
|
| Liver Function Tests | 3 | 2019 | 114 | 0.360 |
Why?
|
| Hepatitis C Antibodies | 2 | 2019 | 19 | 0.340 |
Why?
|
| Humans | 27 | 2021 | 68618 | 0.330 |
Why?
|
| Insurance Carriers | 1 | 2009 | 9 | 0.330 |
Why?
|
| Fee-for-Service Plans | 3 | 2016 | 24 | 0.310 |
Why?
|
| Mammaplasty | 1 | 2007 | 41 | 0.300 |
Why?
|
| Kidney Failure, Chronic | 2 | 2021 | 365 | 0.290 |
Why?
|
| Aged | 10 | 2020 | 14862 | 0.290 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2020 | 307 | 0.280 |
Why?
|
| Female | 16 | 2021 | 38074 | 0.270 |
Why?
|
| Health Maintenance Organizations | 1 | 2006 | 22 | 0.270 |
Why?
|
| Liver | 3 | 2021 | 1118 | 0.260 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 3259 | 0.260 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 378 | 0.260 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 4848 | 0.250 |
Why?
|
| Hospital Mortality | 1 | 2006 | 384 | 0.230 |
Why?
|
| Male | 14 | 2021 | 37321 | 0.230 |
Why?
|
| Retrospective Studies | 10 | 2021 | 7277 | 0.220 |
Why?
|
| Alanine Transaminase | 2 | 2021 | 137 | 0.210 |
Why?
|
| Neoplasms | 4 | 2017 | 1667 | 0.210 |
Why?
|
| Middle Aged | 9 | 2020 | 21147 | 0.180 |
Why?
|
| Hospitalization | 3 | 2020 | 978 | 0.180 |
Why?
|
| Population Surveillance | 2 | 2016 | 285 | 0.180 |
Why?
|
| Vulnerable Populations | 1 | 2021 | 84 | 0.180 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2021 | 87 | 0.180 |
Why?
|
| Brain Ischemia | 1 | 2006 | 665 | 0.170 |
Why?
|
| Graft Survival | 2 | 2019 | 465 | 0.170 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 191 | 0.160 |
Why?
|
| RNA, Viral | 1 | 2019 | 93 | 0.160 |
Why?
|
| Physicians, Primary Care | 1 | 2019 | 46 | 0.160 |
Why?
|
| Referral and Consultation | 1 | 2020 | 383 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 468 | 0.150 |
Why?
|
| Erythropoiesis | 1 | 2017 | 24 | 0.150 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 1070 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2020 | 326 | 0.140 |
Why?
|
| Drug Utilization | 1 | 2017 | 119 | 0.140 |
Why?
|
| Erythropoietin | 1 | 2017 | 96 | 0.140 |
Why?
|
| Equipment and Supplies | 1 | 2016 | 18 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 445 | 0.130 |
Why?
|
| Safety | 1 | 2016 | 145 | 0.130 |
Why?
|
| Models, Statistical | 1 | 2019 | 448 | 0.130 |
Why?
|
| Pharmaceutical Preparations | 1 | 2016 | 101 | 0.130 |
Why?
|
| South Carolina | 2 | 2019 | 2752 | 0.120 |
Why?
|
| Drugs, Investigational | 1 | 2014 | 18 | 0.120 |
Why?
|
| Drug Approval | 1 | 2014 | 50 | 0.120 |
Why?
|
| Risk Factors | 3 | 2019 | 5731 | 0.120 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2014 | 25 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 694 | 0.120 |
Why?
|
| Public Health | 1 | 2016 | 201 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 772 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2016 | 880 | 0.110 |
Why?
|
| Adult | 7 | 2021 | 21403 | 0.110 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 711 | 0.110 |
Why?
|
| Stroke | 1 | 2006 | 2163 | 0.110 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2014 | 148 | 0.110 |
Why?
|
| Veterans | 1 | 2020 | 904 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 1085 | 0.100 |
Why?
|
| Connecticut | 1 | 2011 | 13 | 0.100 |
Why?
|
| Hawaii | 1 | 2011 | 24 | 0.100 |
Why?
|
| Washington | 1 | 2011 | 27 | 0.100 |
Why?
|
| Utah | 1 | 2011 | 27 | 0.100 |
Why?
|
| Linear Models | 1 | 2012 | 521 | 0.090 |
Why?
|
| Mastectomy, Segmental | 1 | 2011 | 64 | 0.090 |
Why?
|
| Heart Failure | 1 | 2020 | 1180 | 0.090 |
Why?
|
| Lymph Node Excision | 1 | 2011 | 91 | 0.090 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 581 | 0.090 |
Why?
|
| Quality of Health Care | 1 | 2012 | 322 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2020 | 2358 | 0.080 |
Why?
|
| Insurance Claim Review | 1 | 2009 | 39 | 0.080 |
Why?
|
| State Government | 1 | 2009 | 34 | 0.080 |
Why?
|
| Neoplasm Staging | 1 | 2011 | 800 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 2 | 2020 | 274 | 0.080 |
Why?
|
| Medically Uninsured | 1 | 2008 | 99 | 0.070 |
Why?
|
| Insurance Coverage | 1 | 2008 | 99 | 0.070 |
Why?
|
| Electronic Health Records | 2 | 2020 | 374 | 0.070 |
Why?
|
| Independent Practice Associations | 1 | 2006 | 2 | 0.070 |
Why?
|
| Least-Squares Analysis | 1 | 2006 | 35 | 0.070 |
Why?
|
| Nursing Homes | 1 | 2006 | 54 | 0.070 |
Why?
|
| Risk Adjustment | 1 | 2006 | 49 | 0.060 |
Why?
|
| International Classification of Diseases | 1 | 2006 | 85 | 0.060 |
Why?
|
| Medicaid | 1 | 2008 | 302 | 0.060 |
Why?
|
| Neurology | 1 | 2006 | 43 | 0.060 |
Why?
|
| Health Services Research | 1 | 2006 | 209 | 0.060 |
Why?
|
| Logistic Models | 1 | 2007 | 1420 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 1046 | 0.050 |
Why?
|
| Length of Stay | 1 | 2006 | 780 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2021 | 104 | 0.050 |
Why?
|
| Aspartate Aminotransferases | 1 | 2021 | 87 | 0.050 |
Why?
|
| Sustained Virologic Response | 1 | 2020 | 11 | 0.050 |
Why?
|
| Time Factors | 2 | 2019 | 4655 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2021 | 174 | 0.050 |
Why?
|
| Self Efficacy | 1 | 2021 | 199 | 0.050 |
Why?
|
| Specialization | 1 | 2020 | 66 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 1851 | 0.050 |
Why?
|
| Geography | 1 | 2020 | 80 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2021 | 219 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2020 | 193 | 0.040 |
Why?
|
| Biopsy | 1 | 2021 | 540 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2019 | 114 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 242 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2020 | 211 | 0.040 |
Why?
|
| Forecasting | 1 | 2019 | 277 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2021 | 301 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2020 | 335 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 792 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2020 | 413 | 0.030 |
Why?
|
| Legislation as Topic | 1 | 2016 | 6 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2019 | 458 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1465 | 0.030 |
Why?
|
| Prognosis | 1 | 2019 | 2093 | 0.030 |
Why?
|
| Decision Making | 1 | 2016 | 410 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2019 | 2007 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2008 | 622 | 0.020 |
Why?
|
| Registries | 1 | 2008 | 733 | 0.010 |
Why?
|